statement
SIM0725 was independently developed by the company.
A statement by 先聲藥業集團. Statements are as reported by the cited publishers — not verified by DecisionGateway.
其自主研發的
Discussion
Related claims
SIM0725 has been approved by the National Medical Products Administration to conduct clinical trials in China.先聲藥業集團 · investigationSIM0725 is intended for the treatment of autoimmune diseases.先聲藥業集團 · statementThis company independently developed the related product.clsvip · statementSIM0725 is a long-acting antagonistic monoclonal antibody targeting the interleukin-2 receptor beta chain (CD122).先聲藥業集團 · statement富創精密 invested in and established a semiconductor technology company.post author · statement瀋陽創啟半導體科技有限公司 recently was established.企查查APP · statement
More claims by 先聲藥業集團
SIM0725 is a long-acting antagonistic monoclonal antibody targeting the interleukin-2 receptor beta chain (CD122).statementSIM0725 is intended for the treatment of autoimmune diseases.statementSIM0725 has been approved by the National Medical Products Administration to conduct clinical trials in China.investigation
All claims by 先聲藥業集團